SCHEMBL4950382

SCHEMBL4950382

Clc1cccc(C2CCN(Cc3nc4cc(Cl)cc5c4n3CCC5)CC2)c1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 5/20 0.56
DRD4 P21917 4/20 0.56
GRM2 Q14416 4/20 0.56
DRD3 P35462 3/20 0.56
KMT2A Q03164 2/20 0.41
NPC1 O15118 2/20 0.41
ALDH1A1 P00352 3/20 0.41
CCR5 P51681 1/20 0.38
MEN1 O00255 1/20 0.38
MCHR1 Q99705 1/20 0.36
ALDH1A2 O94788 1/20 0.36
ALDH2 P05091 1/20 0.36
ALDH3A1 P30838 1/20 0.36
ALDH1A3 P47895 1/20 0.36
MAPT P10636 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4947686 0.91 GRM2 (0.46) DRD2DRD4GRM2DRD3KMT2A
SCHEMBL4947832 0.91 DRD2 (0.48) DRD2DRD4GRM2DRD3KMT2A
SCHEMBL4950333 0.89 DRD2 (0.55) DRD2DRD4GRM2DRD3ALDH1A1
SCHEMBL4949378 0.89 DRD2 (0.47) DRD2DRD4GRM2DRD3MCHR1
SCHEMBL4943868 0.89 DRD2 (0.51) DRD2DRD4GRM2DRD3KMT2A
SCHEMBL4949187 0.86 DRD2 (0.46) DRD2DRD4GRM2DRD3KMT2A
SCHEMBL4948946 0.86 DRD2 (0.44) DRD2DRD4GRM2DRD3MCHR1
SCHEMBL4944033 0.83 GRM2 (0.51) DRD2DRD4GRM2DRD3MCHR1
SCHEMBL4943381 0.83 DRD2 (0.44) DRD2DRD4GRM2DRD3ALDH1A1
SCHEMBL4950360 0.82 GRM2 (0.41) DRD2DRD4GRM2DRD3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080318999-A1 Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators ASTRAZENECA AB (SE) 2008-12-25 US claimed
US-20070032469-A1 Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators ASTRAZENECA AB (SE) 2007-02-08 US claimed
US-20080318999-A1 Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators ASTRAZENECA AB (SE) 2008-12-25 US disclosed
US-20080318999-A1 Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators ASTRAZENECA AB (SE) 2008-12-25 US disclosed
WO-2007018998-A2 TRICYCLIC BENZIMIDAZOLES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2007-02-15 WO disclosed
US-20070032469-A1 Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators ASTRAZENECA AB (SE) 2007-02-08 US disclosed
US-20070032469-A1 Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators ASTRAZENECA AB (SE) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032469-A1 Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators GRM2, GRM1, GRIN2B DRD2 51/4885DRD4 129/4885GRM2 1/4885
US-20080318999-A1 Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators GRM2, GRM1, GRIN2B DRD2 51/4885DRD4 129/4885GRM2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.